New peptides with metal binding abilities and their use as drug carriers.

Many new designed molecules that target efficiently in vitro bacterial metalloproteases were completely inactive in cellulo against Gram negative bacteria. Their activities were limited by the severe restriction of the penetration/diffusion rate through the outer membrane barrier. To bypass this limitation, we have assayed the strategy of metallodrugs, to improve the delivery of hydroxamic acid inhibitors to peptide deformylase. In this metal-chaperone, to facilitate bacterial uptake, the ancillary ligand tris(2-pyridylmethyl)amine (TPA) or di(picolyl)amine (DPA) was functionalized by a tetrapeptide analogue of antimicrobial peptide, RWRW(OBn) (AA08 with TPA) and/or an efflux pump modulator PAβN (AA09 with TPA and AA27 with DPA). We prepared Co(III), Zn(II), and Cu(II) metallodrugs. Using a fluorescent hydroxamic acid, we showed that, in contrast to Cu(II) metallodrugs, Co(III) metallodrugs were stable in the Mueller Hinton (MH) broth during the time required for bacterial assays. The antibacterial activities were determined against E. coli strain wild-type (AG100) and E. coli strain deleted from acrAB efflux pump (AG100A). While none of the PDFinhs used in this study (SMP289 with an indole scaffold, AT015 and AT019 built on a 1,2,4-oxadiazole scaffold) displayed activity higher than 128 μM, all the metallodrugs were active with MICs around 8 μM both against AG100 and AG100A. However, compared to the activities of equimolar combinations of PDFinhs and the free chelating peptides (AA08, AA09, or AA27), they showed similar activities. A synergistic association between AT019 and AA08 or AA09 was determined using the fractional inhibitory concentration with AG100 and AG100A. Combinations of peptides lacking the chelating group with PDFinhs were inefficient. LC-MS analyses showed that the chelating peptides bind Zn(II) cation when incubated in MH broth. These results support the in situ formation of a zinc metallodrug, but we failed to detect it by LC-MS in MH. Nevertheless, this chelating peptides metalated with zinc act as permeabilizers which are more efficient than PAβN to facilitate the uptake of PDFinhs by Gram(-) bacteria.

[1]  L. Mercado,et al.  Antimicrobial activity of trout hepcidin. , 2014, Fish & shellfish immunology.

[2]  H. Nikaido,et al.  Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. , 2012, FEMS microbiology reviews.

[3]  J. Cowan,et al.  Target-directed catalytic metallodrugs , 2013, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[4]  J. Pagés,et al.  New Peptide-based antimicrobials for tackling drug resistance in bacteria: single-cell fluorescence imaging. , 2013, ACS medicinal chemistry letters.

[5]  Chris Orvig,et al.  Metallodrugs in medicinal inorganic chemistry. , 2014, Chemical reviews.

[6]  Trevor W. Hambley,et al.  Metal-Based Therapeutics , 2007, Science.

[7]  R. Hancock,et al.  Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies , 2006, Nature Biotechnology.

[8]  T. Hambley,et al.  Cobalt complexes with tripodal ligands: implications for the design of drug chaperones. , 2012, Dalton transactions.

[9]  L. Burrows,et al.  The Efflux Inhibitor Phenylalanine-Arginine Beta-Naphthylamide (PAβN) Permeabilizes the Outer Membrane of Gram-Negative Bacteria , 2013, PloS one.

[10]  P. Bispo,et al.  Cation Concentration Variability of Four Distinct Mueller-Hinton Agar Brands Influences Polymyxin B Susceptibility Results , 2012, Journal of Clinical Microbiology.

[11]  J. Svendsen,et al.  The pharmacophore of short cationic antibacterial peptides. , 2003, Journal of medicinal chemistry.

[12]  M. Winterhalter,et al.  The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria , 2008, Nature Reviews Microbiology.

[13]  Anshika Sharma,et al.  Peptide deformylase – a promising therapeutic target for tuberculosis and antibacterial drug discovery , 2009, Expert opinion on therapeutic targets.

[14]  D. Knight,et al.  Cobalt Complexes as Antiviral and Antibacterial Agents , 2010, Pharmaceuticals.

[15]  J. Cowan,et al.  Antimicrobial metallopeptides with broad nuclease and ribonuclease activity. , 2013, Chemical communications.

[16]  V. Larue,et al.  Discovery and refinement of a new structural class of potent peptide deformylase inhibitors. , 2007, Journal of medicinal chemistry.

[17]  A. Casini,et al.  Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. , 2013, Chemical Society reviews.

[18]  J. Frère,et al.  Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. , 2008, The Lancet. Infectious diseases.

[19]  T. Meinnel,et al.  New Antibiotic Molecules: Bypassing the Membrane Barrier of Gram Negative Bacteria Increases the Activity of Peptide Deformylase Inhibitors , 2009, PloS one.

[20]  S. Lippard,et al.  Redox activation of metal-based prodrugs as a strategy for drug delivery. , 2012, Advanced drug delivery reviews.

[21]  M. Ohmasa,et al.  Characterization of Cobalt(III) Complexes with L-Penicillaminate. Crystal Structure of (Diethylenetriamine)(L-penicillaminato)cobalt(III) Chloride Monohydrate , 1982 .

[22]  L. Washer,et al.  Managing antimicrobial resistance in intensive care units , 2010, Critical care medicine.

[23]  O. Mazarrasa,et al.  High Concentrations of Manganese in Mueller-Hinton Agar Increase MICs of Tigecycline Determined by Etest , 2009, Journal of Clinical Microbiology.

[24]  P. Dyson,et al.  Metal-based antitumour drugs in the post-genomic era: what comes next? , 2011, Dalton transactions.

[25]  T. Hambley,et al.  Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug. , 2007, Chemistry.

[26]  M. Zasloff Antimicrobial peptides of multicellular organisms , 2002, Nature.

[27]  Nicolas P E Barry,et al.  Exploration of the medical periodic table: towards new targets. , 2013, Chemical communications.

[28]  M. Berenbaum,et al.  A method for testing for synergy with any number of agents. , 1978, The Journal of infectious diseases.

[29]  H. Nikaido Molecular Basis of Bacterial Outer Membrane Permeability Revisited , 2003, Microbiology and Molecular Biology Reviews.

[30]  APPLICATION OF MASS SPECTROMETRIC TECHNIQUES TO THE DIFFERENTIATION OF PAINT MEDIA , 1972 .

[31]  J. Pagés,et al.  Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. , 1998, Microbiology.

[32]  G. Anderegg,et al.  Pyridinderivate als Komplexbildner. XI†. Die Thermodynamik der Metallkomplexbildung mit Bis-, Tris- und Tetrakis[(2-pyridyl)methyl]-aminen , 1977 .

[33]  V. Larue,et al.  New peptide deformylase inhibitors and cooperative interaction: a combination to improve antibacterial activity. , 2012, The Journal of antimicrobial chemotherapy.

[34]  P. Roussel,et al.  Characterization of cobalt(III) hydroxamic acid complexes based on a tris(2-pyridylmethyl)amine scaffold: reactivity toward cysteine methyl ester. , 2012, Inorganic chemistry.

[35]  J. Flavin,et al.  Combating multidrug-resistant Gram-negative bacterial infections , 2014, Expert opinion on investigational drugs.

[36]  Trevor W. Hambley,et al.  Cellular uptake and distribution of cobalt complexes of fluorescent ligands , 2008, JBIC Journal of Biological Inorganic Chemistry.

[37]  J. Cervantes,et al.  Improved Bioactivity of Antimicrobial Peptides by Addition of Amino‐Terminal Copper and Nickel (ATCUN) Binding Motifs , 2014, ChemMedChem.